Skip to content

Efficacy of Bifidobacterium bifidum G9-1 for quality of life in patients with chronic constipatio

Efficacy of Bifidobacterium bifidum G9-1 for quality of life in patients with chronic constipation: a multicenter, double-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031200011
Enrollment
150
Registered
2020-04-13
Start date
2020-07-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic constipation constipation, probiotics, BBG9-1

Interventions

The patients receive oral Bifidobacterium bifidum G9-1 or placebo third per day after meals for 8 weeks

Sponsors

Misawa Noboru
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who are diagnosed functional constipation by ROME criteria (2) Patients who are 20 years old or over and under 85 (3) Patients who can exhibit their consent in a document (4) Patients who have more than one of overall JPAC-QOL score

Exclusion criteria

Exclusion criteria: (1) Patients who have defecation disorders or are suspected defecation disorders (2) Patients who are diagnosed mechanical disorders by colonoscopy within five years (3) Patients who have severe complications (4) Patients who have history or current evidence of celiac disease or inflammatory bowel disease (5) Patients who have severe psychiatric disease (6) Patients who have current evidence of abuse of drugs or alcohol (7) Patients who have history of bifidobacteria allergies and corn starch allergies (8) Patients who had taken new drug therapy for constipation within 2 weeks before entry (9) Patients who had any change in types, dosage,or adiministration of their prescribed drugs for constipation within 2 weeks before entry (10) Patients who are under treatment with other probiotics (11) Patients who had taken new drug therapy as opioid and sleeping pills within 2 weeks before entry (12) Patients who or are going to be participating in other clinical studies (13) Patients who have history or current evidence of Parkinson's disease (14) Patients who are judged as inadequately for study entry

Design outcomes

Primary

MeasureTime frame
The change in JAPAC-QOL score form pre to after 8 weeks intervention

Secondary

MeasureTime frame
The change in JPAC-QOL score from pre-to after 4 weeks intervention The comparison of stool form,degree of sense of incomplete evacuation,degree of straining, days of defecation and frequency of internal use of rescue drugs between at study entry,at 4 weeks drug intervention,at 8 weeks drug intervention The drug compliance Correlation between PAC-QOL score and change in number of days of defecation, stool form, degree of sense of incomplete evacuation and degree of straining

Contacts

Public ContactNoboru Misawa

Yokohama City University Hospital

nobomisa@hotmail.co.jp+81-457872640

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026